Scholar Rock Holding is a biopharmaceutical company committed to discovering and developing innovative medicines that target the transforming growth factor beta (TGFβ) superfamily of proteins to treat serious diseases with high unmet medical need.

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>Scholar Rock is entering a pivotal phase of growth as it prepares for the global launch of its first commercial biologic product while advancing a pipeline of innovative therapies. We are seeking a highly experienced and scientifically grounded Vice President, CMC Technical Development to lead and scale our CMC development organization across early-stage, late-stage, and commercial programs.</div><div><br></div><div>Reporting to the Chief Technical &amp; Quality Officer (CTO/CQO), the VP, CMC Technical Development will own end-to-end technical leadership across Drug Substance (DS), Drug Product (DP), Analytical Development, Cell Line Development, and device-enabled formulation development. This role will also be accountable for establishing and overseeing Manufacturing Science &amp; Technology (MS&amp;T) capabilities to ensure successful process validation, tech transfer, and ongoing support for commercial manufacturing.</div><div><br></div><div>Scholar Rock is translating innovative science into meaningful therapies for patients. With a growing pipeline and our first commercial product on the horizon, this is a unique opportunity to shape the technical foundation of a company at the intersection of scientific excellence and real-world impact.</div>

Vice President, CMC Technical Development

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div><span style="font-size: 11pt">Scholar Rock is seeking an experienced and motivated Director/Sr. Director of Quality Systems and GxP Compliance. Reporting to the Head of Quality, this position will oversee all aspects of quality systems and compliance for commercial, clinical, and development activities. The position is responsible for managing an effective Quality Management System to ensure continued compliance with all global regulatory requirements.</span></div>

Director/Sr. Director, Quality Systems and GxP Compliance

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div><span style="font-size: 10.5pt;">The Head of Regulatory Affairs, Europe, is a leadership position that will be responsible for building and leading the regulatory team to develop and implement regulatory strategies to secure and maintain market access for product(s) in line with business objectives and in coordination with key internal stakeholders. The Head of Regulatory Affairs, Europe, ensures all regulatory and compliance activities across Europe are effectively managed, supporting the distribution, R&amp;D, and marketing of products. This role leads the European Regulatory Affairs team and partners with the European business. The role would also develop regulatory strategy, oversee the filings and manage reviews for gaining market access for the Rest of World.</span></div>

Head of Regulatory Affairs, Europe

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div><span style="font-size: 12pt;">Scholar Rock is seeking a highly experienced and technically strong Senior Director of Drug Product Development to lead formulation and drug product development efforts across our portfolio of biologics, including monoclonal antibodies, fusion proteins, and bispecifics. This role will be responsible for driving drug product strategy and execution across modalities and presentations—from intravenous (IV) to subcutaneous (SubQ), including high-concentration formulations, prefilled syringes (PFS), and autoinjectors (AI). The ideal candidate brings extensive experience in formulation development, process development, tech transfer, and commercial readiness for biologics.</span></div>

Senior Director, Drug Product Development

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>The Medical Director, reporting to the VP, Clinical Research, will be a member of the early development team, accountable for driving clinical development activities for product candidates from IND through Proof-of-Concept. The successful candidate will be responsible for providing medical leadership for clinical development activities of follow-on indication(s) for apitegromab as well as new product candidates, in alignment with corporate strategy. This position requires a highly motivated physician scientist with hands-on expertise in advancing product candidates to deliver life-changing medicines.</div>

Medical Director, Clinical Research

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>The Medical Director, reporting to the SVP, Clinical Research, will be a member of the late-stage development team, accountable for driving clinical development activities for product candidates from Proof-of-Concept through marketing approval and lifecycle management. The successful candidate will be responsible for providing medical leadership for clinical development activities for apitegromab as well as other product candidates entering late-stage development, in alignment with corporate strategy. This position requires a highly motivated physician scientist with hands-on expertise in advancing late-stage product candidates to deliver life-changing medicines.</div>

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>The Senior Director, CMC Program Lead will serve as a strategic and operational leader, overseeing the execution of Scholar Rock’s CMC development and manufacturing programs. This individual will drive cross-functional coordination across Process Development, Analytical Sciences, Manufacturing, Quality, and Regulatory CMC to ensure delivery of key program milestones across the lifecycle—from early development through launch and lifecycle management. The role requires an experienced, proactive leader who thrives in a fast-paced, science-driven biotech environment.</div>

Senior Director, CMC Program Lead

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>The Chief Information Officer (CIO)/VP of IT will lead Scholar Rock’s global IT function through a period of rapid growth, modernization, and strategic transformation. This executive will ensure workplace enablement and IT service reliability today, while defining and executing a forward-looking technology vision that enables global commercialization, compliant operations, and digital innovation.</div><div><br></div><div>A proven builder and scaler of IT organizations and systems, the CIO/VP IT will establish the people, processes, and platforms needed to support Scholar Rock’s growth from a development-stage biotech to a fully integrated global commercial company. The CIO/VP IT will also be a visible leader with regular engagement at the Executive Team and Board level, providing updates on IT performance, cybersecurity, compliance, and digital strategy.</div>

Chief Information Officer, VP of Information Technology

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>Scholar Rock is entering a transformative phase with its first global commercial launch underway and a pipeline of biologics advancing through clinical development. We are seeking a strategic, execution-oriented Head of Global GxP Quality to lead our Quality organization across both commercial and clinical operations.</div><div><br></div><div>Reporting to the Chief Technical &amp; Quality Officer (CTO/CQO), this role will be accountable for building and leading a global, integrated GxP Quality function, spanning GMP, GDP, GCP, GLP, Quality Systems, Quality Control, EU Quality, and post-market surveillance. This is a mission-critical leadership role responsible for ensuring regulatory compliance, global inspection readiness, and operational excellence across the product lifecycle.</div><div><br></div><div>Scholar Rock is advancing life-changing therapies rooted in biologics and deep science. With our first commercial product approaching launch and a pipeline of promising assets, we are building for the long term. This role offers a rare opportunity to lead and shape a global Quality function at one of the most critical and exciting moments in our growth trajectory.</div>

Head of Global GxP Quality

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>Scholar Rock is seeking an accomplished and strategic leader to serve as Vice President, Head of Preclinical Sciences. This individual will be responsible for driving the strategy and execution of all preclinical development activities—including toxicology, DMPK, and bioanalytical sciences to enable IND submissions and support early and late clinical development of our biologics pipeline in neuromuscular and rare diseases. Reporting to the Chief Scientific Officer, the VP will shape preclinical strategy, lead cross-functional execution, and serve as a key contributor to regulatory filings and interactions, and lead all preclinical sciences planning.</div>

Vice President, Head of Preclinical Sciences

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>Reporting to the Sr. Director, FP&amp;A, the Director of FP&amp;A R&amp;D will have responsibility for supporting R&amp;D and pipeline programs at Scholar Rock. The successful candidate will have a proven track record with planning and executing against financial objectives in collaboration with internal functional stakeholders. They will also be a strategic partner in framing, evaluating, and driving decision making to maximize value creation. It will involve clear communication, organization and a great sense of teamwork. This position represents a great opportunity to help build a critical cross-functional capability at a growing and evolving, multi-product candidate biotechnology company.</div>

Director, Financial Planning & Analysis, R&D

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div><span style="font-size: 11pt;">The Director of Development Operations, reporting to Chief Medical Officer, will be a member of the Development Leadership Team, accountable for facilitating effective communication and operational excellence within the development organization. This individual provides scientific and operational support to the CMO, including coordination of scientific engagement, cross-functional alignment, vendor contracting, resource planning and oversight of the development team. The ideal candidate is a proactive, highly organized, and outcome-oriented leader who thrives in a fast-paced, matrixed environment, with exceptional interpersonal skills to drive efficiency and effectiveness of development operations.&nbsp;</span></div>

Director of Development Operations

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div><span style="font-size: 11pt;">The Sr. Medical Director, Drug Safety &amp; Pharmacovigilance is a key position within the company and safety department, with significant impact on the development and life cycle of drug development projects. Responsible for providing safety strategy, expertise, and guidance, pre- and post-approval for assigned products, the Sr. Medical Director will drive the proactive implementation of risk management initiatives in accordance with global regulatory requirements. Core responsibilities will encompass continuous and efficient evaluation of safety data, perform signal detection, evaluation and assessment and management of the safety profile of the compound. In addition, the position will work closely with cross functional teams and Departments for achieving project goals, within timelines &amp; with high quality.</span></div>

Sr. Medical Director, Drug Safety & Pharmacovigilance

<div><i>Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. </i></div><div><i>&nbsp;</i></div><div><i>Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at </i><a rel="noopener noreferrer" class="postings-link" href="http://www.scholarrock.com/"><i>ScholarRock.com</i></a><i> and follow </i><a rel="noopener noreferrer" class="postings-link" href="http://www.twitter.com/scholarrock"><i>@ScholarRock</i></a><i> and on </i><a rel="noopener noreferrer" class="postings-link" href="https://www.linkedin.com/company/scholar-rock"><i>LinkedIn</i></a><i>.</i></div><div><br></div><div><b style="font-size: 18px;">Summary of Position:</b></div><div><br></div><div>Scholar Rock is preparing for its first global commercial launch and is anchoring its Global Supply Chain leadership in Ireland. The Vice President, Global Supply Chain, will serve as the strategic and operational head of Scholar Rock’s worldwide supply chain, accountable for global planning, packaging/labeling, serialization, logistics, distribution, and GDP/GMP compliance.</div><div>This role establishes Ireland as Scholar Rock’s global supply chain hub ensuring compliance with EU MAH/MIA, and full readiness to support product distribution under U.S. FDA, EMA, and Japan PMDA regulatory frameworks. The VP will ensure Scholar Rock’s products are reliably and compliantly supplied across the U.S., EU, Japan, and Rest of World.</div>

Get a job referral to Scholar Rock Holding

Your career is worth investing in.

Get unlimited referrals with Premium.